Braeburn and Camurus report positive top-line results from Phase III trial of CAM2038 for opioid use disorder

Pharmaceutical companies Braeburn and Camurus have reported positive top-line results from a pivotal Phase III trial of buprenorphine (CAM2038) to treat moderate-to-severe opioid use disorder.

Source: Drug Development Technology - November 15, 2016 Category: Pharmaceuticals Source Type: news